Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 14/20 | 1.00 |
| ▸ | MAP4K2 | Q12851 | 6/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | PKN2 | Q16513 | 2/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 2/20 | 1.00 |
| ▸ | SLK | Q9H2G2 | 2/20 | 1.00 |
| ▸ | CDC7 | O00311 | 1/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | DYRK3 | O43781 | 1/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | KIT | P10721 | 1/20 | 1.00 |
| ▸ | PHKG2 | P15735 | 1/20 | 1.00 |
| ▸ | CDK2 | P24941 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | CLK2 | P49760 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29359979 | 1.00 | SYK (1.00) | SYKMAP4K2MAP4K4PKN2AURKB | |
| Hydrochloric Acid SCHEMBL1224258 | 0.99 | SYK (1.00) | SYKMAP4K2MAP4K4PKN2AURKB | |
| Hydrochloric Acid SCHEMBL4075258 | 0.99 | SYK (1.00) | SYKMAP4K2MAP4K4PKN2AURKB | |
| Hydrochloric Acid SCHEMBL31094662 | 0.99 | SYK (1.00) | SYKMAP4K2MAP4K4PKN2AURKB | |
| SCHEMBL6498035 | 0.90 | SYK (1.00) | SYKMAP4K2MAP4K4PKN2AURKB | |
| Hydrochloric Acid SCHEMBL6279261 | 0.90 | MAP4K2 (0.88) | SYKMAP4K2MAP4K4PKN2AURKB | |
| SCHEMBL6505524 | 0.87 | MAP4K2 (0.76) | SYKMAP4K2MAP4K4PKN2AURKB | |
| SCHEMBL6506373 | 0.84 | SYK (0.80) | SYKMAP4K2MAP4K4PKN2AURKB | |
| SCHEMBL6497658 | 0.83 | SYK (0.81) | SYKMAP4K2MAP4K4PKN2AURKB | |
| SCHEMBL6508112 | 0.79 | SYK (0.65) | SYKMAP4K2MAP4K4PKN2AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191098-A1 | COMBINATIONS AND DOSING REGIMES TO TREAT RB-POSITIVE TUMORS | G1 Therapeutics, Inc. (US) | 2017-07-19 | — | — | EP | claimed |
| WO-2016040858-A1 | COMBINATIONS AND DOSING REGIMES TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | claimed |
| US-6911443-B2 | Imidazopyrimidine derivatives and triazolopyrimidine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-06-28 | — | — | US | claimed |
| EP-1278750-B1 | IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-08-04 | — | — | EP | claimed |
| US-20040054179-A1 | Imidazopyrimidine derivatives and triazolopyrimidine derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-03-18 | — | — | US | claimed |
| EP-1278750-A1 | IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2003-01-29 | — | — | EP | claimed |
| WO-2001083485-A1 | IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-11-08 | — | — | WO | claimed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-04-09 | — | — | US | disclosed |
| EP-4223294-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| EP-3925607-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMA (US) | 2023-06-28 | — | — | EP | disclosed |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-24 | — | — | US | disclosed |
| WO-2007118793-A1 | DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-25 | — | — | WO | disclosed |
| US-6911443-B2 | Imidazopyrimidine derivatives and triazolopyrimidine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-06-28 | — | — | US | disclosed |
| EP-1278750-B1 | IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-08-04 | — | — | EP | disclosed |
| US-20040054179-A1 | Imidazopyrimidine derivatives and triazolopyrimidine derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-03-18 | — | — | US | disclosed |
| EP-1278750-A1 | IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001083485-A1 | IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054179-A1 | Imidazopyrimidine derivatives and triazolopyrimidine derivatives | XRCC6, XRN2, HRH2 | SYK 1025/4885MAP4K2 2126/4885MAP4K4 2194/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | SYK 1558/4885MAP4K2 4229/4885MAP4K4 4404/4885 |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | PDE4A, PDE4B, PDE12 | SYK 466/4885MAP4K2 1399/4885MAP4K4 761/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | SYK 1558/4885MAP4K2 4229/4885MAP4K4 4404/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | SYK 1558/4885MAP4K2 4229/4885MAP4K4 4404/4885 |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | SYK 1864/4885MAP4K2 4181/4885MAP4K4 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.